However, in an exploratory study with a panel of NB cell lines, it was noted that inhibition occurs irrespective of ALK mutational status, and cell lines that carry other driver mutations (i.e., MYC amplification) are sensitive to treatment as well. The gene discussed is ALK; the disease is neuroblastoma.